Transcendence PCI

(A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention; Thrombin Receptor AntagoNiSt for Clincial EveNt reduction ovEr StaNdard Concomitant thErapies in PCI)

The Transcendence PCI trial is a multi-center, trial being conducted at 75 centers world-wide enrolling 800 patients. The trial is sponsored by Schering-Plough Corporation. The primary objective of this study is to evaluate the safety of SCH 530348 as an alternative to use of IIb/IIIa inhibitors with respect to incidence of major and minor bleeding events as assessed by the TIMI (Thrombolysis In Myocardial Infarctions cooperative group) system of classification, in addition to the standard of care in subjects undergoing non-urgent PCI and as maintenance therapy (60 days) after the procedure. Patients who have had symptoms of CAD who are scheduled for non-urgent PCI are eligible.

Contant Info Principal Investigator: Ronald P. Karlsberg, MD Study Coordinator: : Maria Thottam, BS Contact number: 310.275.9551

Clinical Trials

Congestive Heart Failure

FUSION II

PROCLAIM

RED HF

Heart Failure Devices

PEGASUS CRT

OPTIMIZER III

Acute Coronary Syndrome

Horizons

Triton – TIMI 38

Coronary Artery Disease

Crescendo

Transcendence PCI

TACT

Carotid Artery Disease

CAPTURE 2

CT Projects

DXV406

DXV301